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    1. INTRODUCTION 
Pharmaceutical Analysis is the branch of Chemistry involved in separating, 
identifying and determining the relative amounts of the components making up a 
sample of matter. It is mainly involved in the qualitative identification or detection 
of compounds and quantitative measurements of the substances present in Bulk drug 
and Pharmaceutical preparations (Sharma B.K, 2000) 
Pharmaceutical Analysis simply means analysis of a Pharmaceutical(s). It is 
generally known that a Pharmaceutical is a chemical entity of Therapeutic interest. 
A more appropriate term for a Pharmaceutical is Active Pharmaceutical Ingredient 
(API) or Active Ingredient. Even though the term Active Ingredient is more 
frequently used, the preferred term is Active Pharmaceutical Ingredient. To 
distinguish it from the formulated product or drug product, API is also called Drug 
substance. The drug product is prepared by formulating a drug substance with inert 
ingredients (excipients) to prepare a drug product that is suitable for administration 
to patients. 
However, it should be recognized that there are situations where a drug 
substance can be administered after simple dissolution in a solvent such as water. 
Even in these situations, a suitable Pharmaceutical treatment has to be conducted to 
assure availability and other safety considerations. 
It is well known in the Pharmaceutical industry that Pharmaceutical Analysts 
in Research and Development (R&D) play a very comprehensive role in new drug 
development and follow up activities to assure that a new drug product meets the 
established standards, is stable and continues to meet the purported quality 
throughout its shelf life. After the drug product is approved by regulatory 
authorities, assuring that all batches of drug product are made to the specified 
standards, utilization of approved ingredients and production methods becomes the 
responsibility of Pharmaceutical Analysts in the Quality Control (QC) or Quality 
Assurance (QA) department. The methods are generally developed in an analytical 
R&D department and transferred to QC or other departments, as needed. At times, 
they are transferred to other divisions located nationally or abroad or to outsourced 
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companies. By now it should be quite apparent that Pharmaceutical Analysts play a 
major role in assuring the identity, safety, efficacy, and quality of a Drug product. 
Safety and efficacy studies require that drug substance and drug product meet two 
critical requirements: 
•   Established Identity and Purity. 
•  Established Bioavailability / Dissolution (Satinder A & Stephen S, 2001) 
Quality Assurance plays a central role in determining the safety and efficacy 
of medicines. Highly specific and sensitive analytical techniques hold the key to the 
design, development, standardization and quality control of medicinal products. 
They are equally important in pharmacokinetics and in drug metabolism studies, 
both of which are fundamental to the assessment of bioavailability and the duration 
of clinical response. However, modern concepts of quality differs and concerned not 
only with chemical purity, but also with those other characteristics of 
Pharmaceutical materials which may influence safety, efficacy, formulation and 
processing of medicines (Beckett AH & Stenlake JB 1997). 
1.1 INSTRUMENTAL ANALYSIS 
The instrument is only one component of the total analysis. Often, it is necessary 
to use several instrumental techniques to obtain the information required to solve an 
analytical problem. Instrumental method may be used by analytical chemists to save 
time, to avoid chemical separation or to obtain increased accuracy. 
Based on Principle Types of Chemical Instrumentation: 
A) Spectrometric Techniques: 
              • Atomic Spectrometry (Emission and Absorption) 
              • Electron Spin Resonance Spectroscopy 
   • Fluorescence and phosphorescence Spectrophotometry 
   • Infrared Spectrophotometry 
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   • Nuclear Magnetic Resonance Spectroscopy 
   • Radiochemical Techniques including activation analysis 
   • Raman Spectroscopy 
   • Ultraviolet and visible Spectrophotometry 
   • X-Ray Spectroscopy 
B) Electrochemical techniques 
• Potentiometry 
• Voltametry 
• Stripping techniques 
• Amperometric techniques 
• Coulometry 
• Electrogravimetry 
• Conductance techniques. 
C) Chromatographic Techniques: 
   • Gas Chromatography 
   • High performance Liquid Chromatography 
   • Thin Layer Chromatography 
D) Miscellaneous Techniques: 
  • Kinetic Techniques 
  • Mass Spectrometry 
  • Thermal Analysis 
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D) Hyphenated Techniques: 
  • GC-MS (Gas Chromatography - Mass Spectrometry) 
  • ICP-MS (Inductivity Coupled Plasma - Mass Spectrometry) 
  • GC-IR (Gas Chromatography - Infrared Spectroscopy) 
  • MS-MS (Mass Spectrometry - Mass Spectrometry (Willard H.H. et al 1986) 
1.1. CHROMATOGRAPHY 
 
 Chromatography (from Greek: chroma, color and:"graphein" to write) is 
essentially a group of techniques for the separation of the compounds of mixtures by 
their continuous distribution between two phases, one of which is moving fast the 
other that depends on differential affinities of the solute between two immiscible 
phases, one of which will be fix with large surface area, while the other is fluid which 
moves through or over the surface of the fixed phase. (Beckett AH & Stenlake JB 
1997) 
Definitions for Chromatography: 
1. Tswett gave the first definition of chromatography. Chromatography is a 
method in which the compounds of a mixture are separated on an adsorbent 
column in a flowing system. 
2. Chromatography defined as a method of separating a mixture of components 
into individual components through equilibrium distribution between two 
phases. (Gurdeep R Chatwal & Sham K.Anand 2002) 
3. IUPAC: chromatography is a physical method of separation in which the 
compound to be separated are distributed between two phases, one of which is 
stationary (stationary phase) while the other (the mobile phase) moves in a 
definite direction (IUPAC, 1993) 
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CLASSIFICATION  OF CHROMATOGRAPHIC METHODS 
(Gurdeep R. Chatwal & Sham K.Ananad 2002) 
STATIONARY 
PHASE 
MOBILE PHASE                      NAME 
SOLID LIQUID 
Plane Chromatography 
Paper Chromatography 
Thin layer Chromatography 
Adsorption Column Chromatography 
High Performance Liquid 
Chromatography 
SOLID 
(Ion exchange resin) 
LIQUID 
Ion exchange Chromatography 
SOLID 
 
GAS 
Gas-Solid Chromatography  
SOLID MATRIX LIQUID 
Gel permeation Chromatography 
(Exclusion Chromatography) 
LIQUID GAS Gas-Liquid Chromatography 
LIQUID LIQUID Liquid-Liquid Chromatoraphy 
 
1.3. HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY  
High Performance Liquid Chromatography (HPLC) was developed in the 
late 1960s and early 1970s. Today it is widely applied for separations and 
purifications in a variety of areas including pharmaceuticals, biotechnology, 
environmental, polymer and food industries.  
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HPLC has over the past decade become the method of choice for the analysis 
of a wide variety of compounds. Its main advantage over GC is that the analytes do 
not have to be volatile, so macromolecules are suitable for HPLC analysis.  
PRINCIPLE: 
HPLC is accomplished by injection of a small amount of liquid sample into a 
moving stream of liquid (called the mobile phase) that passes through a column 
packed with particles of stationary phase. Separation of a mixture into its 
components depends on different degrees of retention of each component in the 
column. Since the compounds have different mobility’s, they exit the column at 
different times; i.e., they have different retention times, Rt. The retention time is the 
time between injection and detection. There are numerous detectors which can be 
used in liquid chromatography. It is a device that senses the presence of components 
different from the liquid mobile phase and converts that information to an electrical 
signal.  
Reversed phase HPLC 
In this case, the column size is the same, but the silica is modified to make it 
non-polar by attaching long hydrocarbon chains to its surface - typically with either 
8 or 18 carbon atoms in them. A polar solvent is used - for example, a mixture of 
water and an alcohol such as methanol.  There will be a strong attraction between 
the polar solvent and polar molecules in the mixture being passed through the 
column. There won't be as much attraction between the hydrocarbon chains attached 
to the silica (the stationary phase) and the polar molecules in the solution. Polar 
molecules in the mixture will therefore spend most of their time moving with the 
solvent. Non-polar compounds in the mixture will tend to form attractions with the 
hydrocarbon groups because of Vander Waals dispersion forces. They will also be 
less soluble in the solvent because of the need to break hydrogen bonds as they 
squeeze in between the water or methanol molecules, for example. They therefore 
spend less time in solution in the solvent and this will slow them down on their way 
through the column. That means that now it is the polar molecules that will travel 
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through the column more quickly. (David C. Lee &Michael Webb, 2003)(Synder 
L.R &Kirkland J.J.,1997) 
The majority of the HPLC separations are done with Reversed phase 
separation, probably over 90%. In reversed phase separations organic molecules are 
separated based on their degree of hydrophobicity. There is a correlation between 
the degree of lipophylicity and retention in the column. 
Types of HPLC techniques 
 Based on Principles of Separations 
• Partition Chromatography 
• Adsorption (liquid-solid) Chromatography 
• Ion exchange  Chromatography 
• Size exclusion Chromatography 
 Based on Modes of Chromatography 
• Normal Phase Chromatography 
• Reverse Phase Chromatography 
 Based on Elution Techniques 
• Isocratic Separation 
• Gradient Separation 
 Based on the Scale of Operation 
• Analytical HPLC  
• Preparative HPLC 
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Flow chart: 1.   Selection of HPLC methods depending upon Nature of samples  
  
 
INSTRUMENTATION: 
1. COLUMN: 
HPLC columns are made of high quality Stainless steel, polished internally to a 
mirror finish. Standard analytical columns are 4-5 m internal diameter and 10-30 cm 
in length, shorter column (3-6 cm in length) containing a small particle size packing 
material (3 or 5 µm). ( Beckett AH& Stenlake J B 1997) 
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Figure 1 : Shcematic representation of HPLC 
               
 
Column packing: 
Three forms of column packing material are available based on a rigid 
structure. These are  
i. Microporous supports 
ii. Pellicular supports 
iii. Bonded phase supports (Gurdeep R.Chatwal &Sham K.Anand,2002) 
2. MOBILE PHASE RESERVIOR : 
The mobile phase reservior can be any clean, inert containers made up of 
stainless steel and glass. Precaution should be taken to present solvents spills in case 
of breakage of the reservoir and it should be placed in plastic container. Solvent 
bottles are available that are coated with a resin material that resist breaking. It 
usually contain 1 or 2 liter of solvent and it should  have a cap that allows the tubing 
inlet line to pass through it. (James W. Munson,2001) 
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  The choice of mobile to be used in any separation depend on the type of 
separation to be achieved. Isocratic separation may be made with a single 
solvent, or two or more solvents mixed in fixed proportion. Alternatively a 
gradient elution system may be used where the composition of the developing 
solvent is continuously changed by use of a suitable gradient programmer. All 
solvents for using HPLC systems must be specially purified since traces of 
impurities can affect the column and interfere with the detection system. It is 
also essential that all solvents are degassed before use other wise gassing tends 
to occur in most pumps. Gassing can alter column resolution and interfere with 
the continues monitoring of the column effluent. Degassing may  be carried out 
in several way; by warming the solvents, by stirring it vigorously with a 
magnetic stir, subjecting it to a vacuum, ultrasonic vibrations or by bubbling 
helium gas through the solvent reservoir.(Gurdeep R.Chatwal & Sham 
K.Ananad,2002) 
The following points should also be considered when choosing a Mobile phase: 
1.  It is essential to establish that the drug is stable in the Mobile phase for at 
least the duration of the analysis. 
2.  Excessive salt concentrations should be avoided. High salt concentrations 
can result in precipitation, which can damage HPLC equipment. 
3.  The Mobile phase should have a pH between 2.5 to pH 7.0 to maximize the 
lifetime of the column. 
4.  Reduce cost and toxicity of the Mobile phase by using methanol instead of 
acetonitrile when possible. 
5.  Minimize the absorbance of buffer. Since trifluroacetic acid or formic acid 
absorb at shorter wavelengths, they may prevent detection of products with 
out chromophores above 220 nm. Carboxylic acid modifiers can be 
frequently replaced by phosphoric acid, which does not absorb above 200 
nm. 
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6.  Use volatile Mobile phases when possible to facilitate collection of products 
and LC - MS analysis. Volatile Mobile phases include ammonium acetate, 
ammonium phosphate, and formic acid, acetic acid and trifluroacetic acid. 
Some caution is needed as these buffers absorb below 220 nm. 
3. INJECTORS: 
Injection ports are of two basic types 
a. Those in which the sample is injected directly into the column 
b. Those in which the sample is deposited before the column inlet and 
then swept by a vying action into the column by the mobile phase. 
           On –column injection involves the injection of the sample by means of a 
syringe through a septum into the center of the packing material. The column and 
the capacity of the packing material is typically 5-25µl for analytical column. 
         High- pressure syringes that can be used at pressure up to 650 atmospheres 
allow the injection of the sample while the mobile phase is flowing. While using 
Low- pressure syringes the flow must be stopped. 
       Modern injectors are based on injection valves which allow the sample at 
atmospheric pressure to be transferred to the high-pressure mobile phase immediately 
before the column inlet. With the injection in LOAD position, the sample is injected 
from a syringe through a needle port into the loop. 
The valve lever is then turned through 60o to the inject position and the sample is 
swept into the flowing mobile phase. An excess of sample is flushed through the loop in 
the LOAD position, the volume injected is the volume of the loop, which is typically 
10-20µl for analytical separation. (Beckett AH& Stenlake J B 1997) 
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4. PUMPS: 
       The pumping system is one of the most important features of a HPLC system. 
There is a high resistance to solvent due to the narrow columns packed in small 
particles, high pressure are required to achieve satisfactory flow rate. 
  The requirements for an HPLC pumping system are several; 
 They include 
a. The generation of pressures of up to 6000 psi (lbs/in2)  
b. Pulse- free output 
c. Flow rates ranging from 0.1 to 10ml/min 
d. Good flow control capacity 
e. All materials in the pump should be chemically resistance to all solvents 
These pumping system available which operate on the principle of constant 
pressure or constant displacement. 
Constant pressure pumps produce a pulse less flow through the column, but 
any decrease in the permeability of the column will result in lower flow rates for 
which the pumps will not compensate. These pumps operate by the introduction of 
high pressure gas into the pump, and the gas in turn forces the solvent from the 
pump chamber in to the column. The intermediate solvent between the gas and the 
eluting solvent reduce the chances of dissolved gas directly enter in the eluting 
solvent and causing problems during the analysis. 
        Constant displacement pump maintain a constant flow rate through the 
column irrespective of changing conditions with in the column. One form of 
constant displacement pump is a motor-driven syringe type pump where a fixed 
volume of solvent is forced from the pump to the column by a piston driven by a 
motor. Such pumps, as well as providing uniform solvents flow rates, also yields a 
pulse less solvent flow which is important as certain in detectors are sensitive to 
change in solvent flow rate. 
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      The reciprocating pump is most commonly used form of constant 
displacement pump. The piston is moved by a motorized crank and entry of solvent  
from the reservoir to the pump chamber and exit of solvent to the column is 
regulated by check valves. On the compression stroke solvent is forced from the 
pump chamber in to the column. During the return stroke the exit check valve closes 
and solvent is drawn in via entry valve to t e pump chamber, ready to be pumped on 
to the column on the next compression stroke. (Gurdeep R.chatwal &Sham K. 
Anand,2002) 
5. DETECTORS: 
The detector for an HPLC is the compound that emits a response due to the 
eluting sample compound and subsequently signals a peak on the chromatogram. It 
is positioned immediately posterior to the stationary phase on order to detect the 
compounds as they elute from the column. The bandwidth and height of the peaks 
may usually be adjusted using the coarse and fine tuning controls, and the detection 
and sensitivity parameters may also be controlled (in most cases). There are many 
types of detectors that can be used with HPLC 
Types of Detectors  
1. Solute specific detectors (UV, visible, fluorescence, electrochemical, infra-
red, radioactivity). 
2. Bulk property detectors (refractive index, viscometer, conductivity). 
3. Desolvation detectors (flame ionization etc.). 
4. LC-MS detectors. 
5. Reaction detectors.  
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Absorbance Detectors 
Absorbance detectors is a typical, Z- shaped, flow through cell for 
absorbance measurements on eluent from chromatographic column. Volumes are 
limited to 1 to 10 µl and cell lengths to 2 to 10 mm, and the pressure not greater than 
600 psi. Many Absorbance detectors are double-beam devices in which one beam 
passes through the eluent cell and the other through a filter to reduce the intensity.   
Ultraviolet Absorbance Detectors 
UV Absorbance Detectors are available in two types, UV Absorbance 
Detectors with Filter and with monochromators. Most HPLC manufactures offer 
detectors that consist of a scanning spectrophotometer with grating optics. Some are 
limited to UV radiation; others encompass both UV and Visible radiation. The most 
powerful UV Spectrophotometric detectors are diode - array instruments. 
Refractive Index Detectors 
RI Detectors are also called as Universal analyte detector. RI detectors have 
the significant advantage of responding to nearly all solutes. That is they are general 
detectors analogous to flame detectors in gas chromatography. In addition they are 
reliable and unaffected by flow rate. They are highly temperature sensitive and must 
be maintained at a constant temperature to a few thousands of a degree centigrade. 
They are not as sensitive as most other type of detectors and generally cannot be 
used with gradient elution. 
Fluorescence Detectors 
Excitation wavelength generates fluorescence emission. Analytes must 
contain a Flurophore group it reacts with the same group of the reagent. The inherent 
advantage of fluorescence methods is their high sensitivity. Results are dependent up 
on the separation condition. (Gennaro A.R.Remigton, 2000) 
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1.4. STEPS FOR ANALYTICAL DEVELOPMENT 
          Methods are developed for new products when no official methods are 
available. Alternate methods for existing (non-pharmacopoeial) products are 
developed to reduce the cost and time for better precision and ruggedness. Trial runs 
are conducted, method is optimized and validated. 
1. Analyte standard characterization: 
a)   All information about the analyte i.e., physical and chemical properties, toxicity, 
b)  The standard analyte (100% purity) is obtained. Made an arrangement for the 
proper storage (refrigerator, desiccators and freezer). 
c)  When multiple components are to be analyzed in the sample matrix, the number 
of components is noted, data is assembled and the availability of standards for 
each one is determined. 
d)  Only those methods (MS, GC, HPLC etc.,) that are compatible with sample 
stability are considered. 
2. Method requirements: 
The goals of the analytical method that need to be developed are considered. 
The detection limits, selectivity, linearity, range, accuracy and precision are defined. 
3. Literature search and prior methodology: 
The information related to the analyte is surveyed for synthesis, physical and 
chemical Properties, solubility and relevant analytical methods. Books, periodicals 
and USP / NF, and publications are reviewed. Chemical Abstracts Service (CAS) 
automated computerized literature searches are convenient. 
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4. Choosing a method: 
a) Using the information in the literatures, methodology is adapted. The 
methods are modified wherever necessary. Sometimes it is necessary to acquire 
additional instrumentation to reproduce, modify, improve or validate existing 
methods for in-house analytes and samples. 
b) If there are no prior methods for the analyte in the literature, from 
analogy, the compounds that are similar in structure and chemical properties are 
investigated and are worked out. There is usually one compound for which 
analytical method already exist that is similar to the analyte of interest. 
 
5. Instrumental setup and initial studies: 
a) The required instrumentation is setup Installation, operational and 
performance qualifications of instrumentation verified by using laboratory Standard 
Operating Procedures (SOP’s). 
b) Always new solvents, filters are used, for example, method development 
is never started, on a HPLC column that has been used earlier. 
c) The analyte standard in a suitable injection / introduction solution and in 
known concentrations and solvents are prepared. It is important to start with an 
authentic, known standard rather than with a complex sample matrix. If the sample 
is extremely close to the standard (e.g., Bulk drug), then it is possible to start work 
with the actual sample. 
d) Analysis is done using analytical conditions described in the existing 
literature. 
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6. Optimization: 
During optimization one parameter is changed at a time, and set of 
conditions are isolated, rather than using a trial and error approach. Work has been 
done from an organized methodical plan, and every step is documented (in a lab 
notebook) in case of dead ends. 
7. Documentation of analytical figures of merit: 
The originally determined analytical figures of merit Limit of Quantitation 
(LOQ), Limit of Detection (LOD), linearity, time per analysis, cost, sample 
preparation etc., are documented. 
8. Evaluation of method development with actual samples: 
The sample solution should lead to unequivocal, absolute identification of 
the analyte peak of interest apart from all other matrix components. 
9. Determination of percent recovery of actual sample and demonstration of 
quantitative sample analysis: 
a) Percent recovery of spiked, authentic standard analyte into a sample 
matrix that is shown to contain no analyte  is determined. Reproducibility of 
recovery (average +/- standard deviation) from sample to sample and whether 
recovery has been optimized is determined. It is not necessary to obtain 100% 
recovery as long as the results are reproducible and known with a high degree of 
certainty. 
b) The validity of analytical method can be verified only by laboratory 
studies. Therefore documentation of the successful completion of such studies is a 
basic requirement for determining whether a method is suitable for its intended 
applications.( Michael E & Schartz IS) 
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1.5. OPTIMIZATION OF CHROMATOGRAPHIC CONDITION 
Optimization can be started only after a reasonable chromatogram has been 
obtained. A reasonable chromatogram means that all the compounds are detected by 
more or less symmetrical peaks on the chromatogram. By a slight change of the 
mobile phase composition, the shifting of the peaks can be expected. From a few 
experimental measurements, the position of the peaks can be predicted within the 
range of investigated changes. An optimized chromatogram is the one in which all 
the peaks are symmetrical and are well separated in less run time.  (Munson 
J.W,1994 ) 
The peak resolution can be increased by using a more efficient column with 
higher theoretical plate number, N.  
 The parameters that are affected by the changes in chromatographic 
conditions are, 
• Resolution (Rs), 
• Capacity factor (k’), 
• Selectivity (α), 
• Column efficiency (N) and 
• Peak asymmetry factor (As). 
i) Resolution (Rs) 
The resolution, Rs, of two neighboring peaks is defined by the ratio of the 
distance between the two peak maxima. It is the difference between the retention 
times of two solutes divided by their average peak width. For baseline separation, 
the ideal value of Rs is 1.5. It is calculated by using the formula, 
                                           Rs   = ( )21
12
5.0 WW
RtRt
+
−
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Where, Rt1 and Rt2 are the retention times of components 1 and 2 and  
             W1 and W2 are peak widths of components 1 and 2. 
ii) Capacity factor (k’) 
Capacity factor, k’, is defined as the ratio of the number of molecules of 
solute in the stationary phase to the number of molecules of the same in the mobile 
phase. Capacity factor is a measure of how well the sample molecule is retained by a 
column or TLC plate during an isocratic separation. The ideal value of k’ ranges 
from 2-10. Capacity factor can be determined by using the formula, 
                              k’   = S
V
VV
×
−
0
01
 
Where,  V1  =  retention volume at the apex of the peak (solute) and  
  V0  = void volume of the system. 
The values of k’of individual band increase or decrease with changes in 
solvent strength. In reverse phase HPLC, solvent strength increases with the increase 
in the volume of organic phase in the water / organic mobile phase. Typically an 
increase in percentage of the organic phase by 10 % by volume will decrease k’ of 
the bands by a factor of 2-3.  
iii) Selectivity (α) 
The selectivity (or separation factor), α, is a measure of relative retention of 
two components in a mixture. The ideal value of selectivity is 2. It can be calculated 
by using the formula,   
                                                          α     =   
01
02
VV
VV
−
−
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Where, V0 is the void volume of the column and V2 and V1 are the retention 
volumes of the second and the first peak respectively. 
iv) Column efficiency (N) 
Efficiency, N, of a column is measured by the number of theoretical plates 
per meter. It is a measure of band spreading of a peak. Smaller the band spread, 
higher is the number of theoretical plates, indicating good column and system 
performance. Columns with N ranging from 2000 - 100,000 plates/meter are ideal 
for a good system. Efficiency is calculated by using the formula, 
N   =   2
2
16
W
Rt
, 
Where, Rt is the retention time and W is the peak width. 
v) Peak Asymmetry factor (As) 
Peak asymmetry factor, can be used as a criterion of column performance. 
The peak half width, b, of a peak at 10 % of the peak height, divided by the 
corresponding front half width, a, gives the asymmetry factor. 
         As =
a
b
   
For a well packed column, an asymmetry factor of 0.9 to 1.1 should be  
achievable. (Jeffery G.H et al , 2003) 
1.6. VALIDATION  
The word “validation” means “Assessment” of validity or action of validity 
or action of providing effectiveness’. Validation is, of course, a basic requirement to 
ensure quality and reliability of the results for all analytical applications. However, 
in comparison with Analytical Chemistry, in Pharmaceutical Analysis, some special 
aspects and conditions exist that need to be taken into consideration. Validation of 
an analytical method is the process by which it is established by laboratory studies, 
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that the performance characteristics of the method meet the requirements for the 
intended analytical applications. 
Definitions:  
 Validation is a systematic approach to gathering and analyzing sufficient 
data which will give reasonable assurance (documented evidence), based upon 
scientific judgment, that a process, when operating within specified parameters, will 
consistently produce results within predetermined specifications. 
         Validation is defined as follows by different agencies: 
European Committee (EC):  
Action of providing in accordance with the principles of Good 
Manufacturing Practice (GMP) that any procedure, process, equipment, material, 
activity or system actually leads to the expected results. In brief validation is a key 
process for effective Quality Assurance 
Food and Drug Administration (FDA): 
            Provides a high degree of assurance that specific process will consistently 
produce a product meeting its predetermined specification and quality attributes. 
World Health Organization (WHO):  
           Action of providing that any procedure,  process, equipment, material, 
activity, or system actually leads to the expected results. 
History: 
Since the mid-1970s validation has become an increasingly dominant 
influence in the manufacturer and quality assurance of pharmaceutical products. In 
1976 the FDA proposed a whole set of current GMP regulations which were revised 
several times. 
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Objective of the Validation 
There are two important reasons for validating assays in the Pharmaceutical 
Industry.  
• The first, and by for the most important, is that assay validation is an 
integral part of the quality control system. 
• The second is that current Good Manufacturing Practice (GMP) 
regulation requires assay validation. In industry it would be difficult 
to confirm that the product being manufactured is uniform and that 
meet the standards set to assure fitness for use. The varying nature of 
the differences between the analytical development laboratory and 
quality control laboratory is a good reason for validation 
program.(USP 1985) ( Joachim Ermer& Miller2005) 
ANALYTICAL METHOD VALIDATION  
Method Validation is the process of proving that an analytical method is 
acceptable for its intended purpose. Methods need to be validated or revalidated- 
Before their introduction into routine use, whenever the conditions change for which 
the method has been validated, whenever the method is changed and the change is 
outside the original scope of the method. 
• United States Pharmacopoeia (USP). 
• Food and Drug Administration (FDA). 
• World Health Organization (WHO). 
• International Conference on Harmonization (ICH). 
These guidelines provide a framework for performing Validation. In general, 
methods for routine analysis, standardization or regulatory submission must include 
studies on specificity, linearity, accuracy, precision, range, limit of detection, limit 
of Quantitation and robustness. 
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In the early stages of drug development, it is usually not necessary to perform all of 
the various validation studies. Many researchers focus on specificity, linearity, 
accuracy, and precision studies for drugs in the preclinical through Phase II 
(preliminary efficacy) stages. The remaining studies are performed when the drug 
reaches the Phase III (efficacy) stage of development and has a higher probability of 
becoming a marketed product. The process of validating a method cannot be 
separated from the actual development of the method conditions, because the 
developer will not know whether the method conditions are acceptable until 
validation studies are performed. The development and validation of a new 
analytical method may therefore be an iterative process. Results of validation studies 
may indicate that a change in the procedure is necessary, which may then require 
revalidation. 
During each validation study, key method parameters are determined and 
then used for all subsequent validation steps. To minimize repetitious studies and 
ensure that the validation data they are generated under conditions equivalent to the 
final procedure. (Mark JG.) 
Benefits of Method Validation:  
A fully validated process may require less in-process control and end product 
testing. It deepens the understanding of processes, decrease the risks of processing 
problems, and thus assure the smooth running of the process.(WHO 1999) 
Validation Parameters of Analytical Method:  
According to ICH guidelines, typical analytical performance characteristics 
that should be considered in the validation of the types of methods are 
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Typical Validation Characteristics which should be considered are: 
 
Figure 5:  The USP and ICH Method Validation Parameter 
 
1. Accuracy: 
The accuracy of an analytical procedure expresses the closeness of 
agreement between the value, which is accepted either as a conventional true value 
or an accepted reference value and the value found. 
The ICH documents recommended that accuracy should be assessed using a 
minimum of nine determinations over a minimum of three concentrations levels the 
specified range (i.e., three concentrations and three replicates of each concentration). 
Accuracy was tested (% Recovery and % RSD of individual measurements) by 
analyzing samples at least in triplicate, at each level (80,100 and 120 % of label 
claim) is recommended. For each determination fresh samples were prepared and 
assay value is calculated. Recovery was calculated from following regression 
equation obtained in linearity study. 
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The % recovery was calculated using the formula, 
100
)(
covRe%
bX
aba
ery −+=  
         Where, 
          a – Amount of drug present in sample 
           b – Amount of standard added to the sample 
2. Precision: 
The precision of an analytical procedure expresses the closeness of 
agreement (degree of scatter) between series of measurements obtained from 
multiple sampling of the same homogenous sample under the prescribed conditions. 
Precision may be considered at three levels: repeatability, intermediate 
precision and reproducibility. Precision should be investigated using homogeneous, 
authentic samples. However, if it is not possible to obtain a homogeneous sample it 
may be investigated using artificially prepared samples or a sample solution. The 
precision of an analytical procedure is usually expressed as the variance, standard 
deviation or coefficient of variation of a series of measurements. The ICH 
documents recommend the repeatability should be assessed using a minimum of 
nine determinations covering specified range of procedure. 
2.1) Repeatability: 
Repeatability expresses the precision under the same operating conditions 
over a short interval of time. Repeatability is also termed intra-assay precision. 
2.2) Intermediate Precision: 
Intermediate precision expresses with in laboratories variations: different 
days, different analyst and different equipment. 
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2.3) Reproducibility: 
When the procedure is carried out by different analyst in different 
laboratories using different equipment, regents and laboratories setting 
reproducibility was determined by measuring repeatability and intermediate 
precision. Reproducibility is assessed by means of an inter-laboratory trial. 
3. Specificity: 
An ICH document defines Specificity is the ability to assess unequivocally 
the analyte in the presence of components which may be expected to be present. 
Typically these might include impurities, degradants, matrix, etc. Lack of specificity 
of an individual analytical procedure may be compensated by other supporting 
analytical procedure(s). 
 The definition has the following implications: 
Identification test:    
                 To ensure identity of an analyte. 
Purity test: 
                To ensure that all the analytical procedures performed allow an accurate 
statement of the content of impurity of the content of impurity of an analyte i.e. 
related substances test, heavy metals, residual solvents etc. 
Assay:  
              To provide an exact result, this allows an accurate statement on the content 
or potency of the analyte in a sample. 
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4. Limit of Detection (LOD): 
The detection limit of an individual analytical procedure is the lowest 
amount of analyte in a sample which can be detected but not necessarily quantitated 
as an exact value. The detection limit is usually expressed as the concentration of 
analyte (percentage parts per million) in the sample. 
Determination of Detection Limit: 
For instrumental and non-instrumental methods detection limit is generally 
determined by the analysis of samples with known concentration of analyte and by 
establishing the minimum level at which the analyte can be reliably detected.                                      
LOD    =    3.3 σ / S 
Where  
σ     =    the standard deviation of the response.  
S     =    the slope of the calibration curve (of the analyte) 
5. Limit of Quantitation (LOQ): 
The Quantitation limit of an individual analytical procedure is the lowest 
amount of analyte in a sample which can be quantitatively determined with suitable 
precision and accuracy. The Quantitation limit is a parameter of quantitative assays 
for low levels of compounds in sample matrices, and is used particularly for the 
determination of impurities and/or degradation products. Quantification limit is 
expressed as the concentration of analyte (e.g. - % ppms) in the sample. 
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Determination of Quantification Limit 
For instrumental and non- instrumental methods, the Quantitation limit is 
generally determined by the analysis of samples with known concentration of 
analyte and by establishing the minimum level at which the analyte can be 
determined with acceptable accuracy and precision. 
LOQ    = 10 σ / S 
Where 
σ   = the standard deviation of the slope 
S   = the slope of the calibration curve (of the analyte) 
5.1) Based on Standard Deviation of the Blank 
Measurement of the magnitude of analytical background response is 
performed by analyzing an appropriate number of blank samples and calculating the 
standard deviation of these responses. 
5.2) Based on the Calibration Curve 
A specific calibration curve should be studied using samples, containing an 
analyte in the range of LOQ. The residuals SD of regression line or the SD of 
intercepts of regression lines may be used as the SD. The quantitative limit is a 
parameter of quantitative assay for low levels of compounds in sample matrices, and 
is use particularly for the determination of impurities or degradation products. 
6. Linearity: 
          The Linearity of an analytical procedure is its ability (within a given range) to 
obtain test results, which are directly proportional to the concentration (amount) of 
analyte in the sample.The linearity is determined from 60% of the ICH reporting 
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level to 140 % of the proposed shelf life specifications of the related substance as a 
minimum. 
7. Range: 
The range of an analytical procedure is the interval between the upper and 
lower of analyte, which is studied.  
The range of an analytical procedure was the concentration interval over 
which acceptable accuracy, precision and linearity were obtained. In practice, the 
range was determined using data from the linearity and accuracy studies. Assuming 
that acceptable linearity and accuracy (recovery) results were obtained as described 
earlier. The only remaining factor to be evaluated was precision. To confirm the 
‘range’ of any analytical procedure, linearity studies alone are not sufficient, and 
accuracy at each concentration (minimum three concentration levels covering lower 
and upper levels) should be proved. 
8. Ruggedness: 
Degree of reproducibility of test results obtained by the analysis of the same 
samples under a variety of condition such as different laboratories, different 
analysts, different instruments etc, normally expressed as the lack of influence on 
test results of operational and environmental variable of the analytical method. 
Ruggedness is a measurement of reproducibility of test results under the variation in 
condition normally expected from laboratory to laboratory and from analyst to 
analyst. Degree of representative of test results is then determined as a function of 
the assay variable. 
9. Robustness: 
Robustness of an analytical method is measure of its capacity to remain 
unaffected small but deliberate variations in method parameters and provides an 
indication of its reliability during normal usage. (www.waters.com, USP 
specification) (ICH Guidelines 1996) 
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Table C:  Acceptance criteria of validation for HPLC 
   S.No.     Characteristics             Acceptance criteria 
1. Accuracy Recovery 98-102% with 80,90,100,120 
spiked sample 
2. Precision  
    - 
a) Repeatability RSD  <  2 
b) Intermediate precision RSD  <  2 
3. Specificity / Selectivity No interference 
4. Detection limit S/N > 2 or 3 
5. Quantitation limit S/N > 10 
6. Linearity  r2 > 0.999 
7. Range 80 - 120% 
8. Stability   >24hr or < 8hr 
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2. LITERATURE REVIEW 
          Systematic literature survey is the main basis for the planning of any scientific 
work and due to the same reasons here the review of literature regarding estimation 
of cefixime in oral suspension dosage formulation  
1. Andrew J. Falkowski, Zee M. Look, Hideyo Nouguchi, B. Michael Silber. 
Determination of cefixime in biological samples by RP-HPLC. Journal of 
Chromatography 1987; 422: page no:145-52 The Cefixime Trihydrate and 
Sulbactam Sodium belong to a group of Anti-bacterial drugs. A Simple, Rapid, 
Specific and economic Reverse phase High Performance Liquid Chromatographic 
(RP- HPLC) method has been developed for assaying both the drugs in 
combinational dosage form. Method involves elution of Cefixime Trihydrate and 
Sulbactam Sodium in Hyper ODS2, Column C18, 150 x 4.6 mm (5 µm) using 
mobile phase composition of a mixture of 45 ml Acetonitrile and 55 ml of water, pH 
6.5 adjusted with OPA at flow rate 1ml/min and analytes were monitored at 254 
nm.Method has been validated according to ICH (International Conference on 
Harmonization) Guideline. 
2. Dhoka M, Gawande V, Joshi P, Simultaneous Estimation of Cefixime Trihydrate 
and Erdosteine in Pharmaceutical Dosage form by using reveres phase – High 
Performance Liquid Chromatography, International Journal of ChemTech Research, 
Jan-Mar 2010, Vol.2, No.1, page no:79-87. simple, precise, and sensitive high-
performance liquid chromatographic method was developed and validated for the 
simultaneous determination of potassium clavulanate and cefixime in synthetic 
mixture form. The analytes were separated on a C18 column by using 0.03 M 
disodium hydrogen phosphate buffer (pH 6.5)methanol (84 + 16, v/v) as the mobile 
phase with detection at 220 nm. The method exhibited high sensitivity and good 
linearity in the concentration ranges of 12.562.5 and 200 mg/mL for potassium 
clavulanate and cefixime, respectively. The total run time for the 2 components was 
<8 min, and the average recovery was >101.5 with a relative standard deviation of 
<1.0. The proposed method was validated according to guidelines of the 
International Conference on Harmonization by evaluation of linearity, recovery, 
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selectivity, robustness, limits of detection and quantitation, and within- and between-
day precision. The results obtained for the synthetic mixture show that the method is 
highly precise and accurate for the simultaneous determination of potassium 
clavulanate and cefixime. 
 3. Eric-Jovanovi S, Agbaba D, Zivanov-Stakic D, Vladimirov S. HPTLC 
determination of cephalosporins in dosage forms. Journal of Pharmaceutical and 
Biomedical Analysis 1998; 18: page no 893-98.  A simple, precise, accurate, and 
sensitive RP-HPLC method for simultaneous determination of cefixime trihydrate 
and dicloxacillin sodium in combined tablet dosage form was developed and 
validated. Chromatographic separation of the two drugs was performed on a 
Purospher BDS C18 column (25 cm 4.6 mm id, 5 m particle size). The mobile phase 
methanol0.01 M phosphate buffer (75 + 25, v/v), adjusted to pH 3 with glacial acetic 
acid, was delivered at a flow rate of 1.0 mL/min. Detection was performed at 227 
nm. Separation was completed within 10 min. Calibration curves were linear with 
R2 between 0.99 to 1.0 over a concentration range of 210 g/mL for cefixime 
trihydrate and 525 /mL for dicloxacillin sodium. The RSD for intraday and interday 
precision was <2.0. 
 4. Global Quality Guideline. Validation of Analytical Procedures. 2002; Number: 
G-6.9, Version: 1.0.. page no 620-667 A simple and accurate method to determine 
tadalafil (TAD) in pure powder and tablet dosage form was developed and validated 
using HPLC. The separation was achieved on an Xterra RP18 column (150 4.6 mm 
id, 3.5 m) in the isocratic mode using bufferacetonitrile (70 + 30, v/v), adjusted to 
pH 7.00 0.05 with triethylamine as the mobile phase at a flow rate of 1.0 mL/min. 
The photodiode array detector was set at 225 nm. Quantification was achieved over 
the concentration range of 50.7152.10 g/mL with mean recovery of 100.26 0.75. The 
method was validated and found to be simple, accurate, precise, and specific. The 
method was successfully applied for the determination of TAD in pure powder and 
tablet dosage form without interference from common excipients or degradation 
products.  
5. Khan U, Sharif S, Ashfaq M, Asghar N, Simultaneous Determination of 
Potassium Clavulanate and Cefixime in Synthetic Mixtures by High Performance 
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Liquid Chromatography, Journal of AOAC International, July 1 2008, Vol 91, page 
no 744-749 Two sensitive and reproducible methods are described for the 
quantitative determination for the simultaneous estimation of cefixime trihydrate and 
ambroxol hydrochloride. The first method was based on HPTLC followed by 
densitometric measurements of their spots at 254 nm. The separation was on HPTLC 
aluminium sheets of silica gel 60 F254 using acetonitrile: methanol: triethylamine 
(8.2:1:0.8, v/v/v) as mobile phase. The linear regression analysis was used for the 
regression line in the range of 200 - 1000 ng spot-1 for cefixime and ambroxol, 
respectively. This system was found to give compact spots for cefixime and 
ambroxol, after development. The second method was based on HPLC separation of 
the two drugs on the column [C18 (5 µ, 25 cm×4.6 mm, i.d.)] at ambient 
temperature using a mobile phase consisting of acetonitrile: methanol (50:50, v/v). 
Quantitation was achieved with UV detection at 254 nm based on peak area with 
linear calibration curves at concentration ranges 4 - 18 and 4 - 28 µg mL-1 for 
cefixime and ambroxol, respectively. Both methods have been successively applied 
to pharmaceutical formulation. No chromatographic interference from the tablet 
excipients was found. Both methods were validated in terms of precision, 
robustness, recovery and limits of detection and quantitation 
6. Kumudhavalli M, Sahu S, Abhiteja K, Jayakar B, Development and Validation of 
RP-HPLC method for simultaneous determination of Cefixime and Potassium 
Clavulanate in Tablet Dosage Form, International Journal of Pharma Recent 
Research, June-September 2010, Vol  No 2. page no 320-345, page no 2A simple 
and sensitive reversed phase High Performance Liquid Chromatographic method has 
been developed and validated for the simultaneous analysis of the Cefixime 
trihydrate (CEF) and Linezolid (LIN) in tablet dosage form. The separation was 
carried out using mobile phase consisting of buffer and methanol with pH 2.5 in the 
ratio of 70:30, v/v. The column used was ACE 5 C18, (150 mm x 4.6 mm i.d., 5 µm) 
with flow rate 1.2 ml/min using PDA detection at 250 nm. The method was linear 
over a concentration range of 23.33 – 40 µg/ml and 70 – 120 µg/ml for CEF and 
LIN, respectively.  
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                         3. AIM AND OBJECTIVE OF WORK 
The drug analysis plays an important role in the development of drugs, their 
manufacture and the therapeutic use. Pharmaceutical industries rely upon 
quantitative chemical analysis to ensure that the raw materials used and the final 
product obtained meets the required specification. The number of drugs and drug 
formulations introduced in to the market has been increasing. These drugs or 
formulation may be either in the new entities in the market or partial structural 
modification of the existing drugs  
 The single component dosage form proves to be effective due to the mode of 
action on the body. The dosage forms including the presence of drug entities possess 
considerable challenge to the analytical chemist during the development of related 
substance procedure. 
 For the present study of Cefixime was selected. The extensive literature 
survey carried out and revealed that there is one method reported for the Related 
substance of cefixime oral suspension. Hence an attempt was made to develop a 
specific, precise, accurate, linear, simple, rapid, validated and cost effective RP-
HPLC method for the  study of these drugs in the dosage forms. 
 
  
                               4.  PLAN OF WORK 
 To develop and validate an effective RP – HPLC method for the estimation of 
Cefixime in bulk and its pharmaceutical dosage forms. 
So ,the plan of work for the designed study was as follows: 
• Gathering physical chemical properties of drug 
• From the UV- analysis ,selection of  λ max 
• Selection of chromatographic condition 
 Selection of stationary phase 
 Selection of  mobile phase  
 Selection of flow rate 
 Selection of Initial separation condition 
• Optimization of chromatographic condition 
• Validation of proposed method 
• Applying developed method to the marketed formulation. 
• Summarize methodology, finalize documentation. 
 
 
 Chapter 5                                                                                                                                                         Drug Profile 
 
Department Of Pharmaceutical Analysis             36               J.K.K. Nataraja College Of Pharmacy 
  
5.  DRUG PROFILE 
Cefixime Trihydrate 
Structure : 
 
Chemical name :  (6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxy       
methoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-          
azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.  
Description : White to light yellow, crystalline power 
 
Molecular formula   : C16H15N5O7S2·3H2O 
 
Molecular mass        : 507.50 g/mol 
 
Bioavailability          : 40-50% 
 
Half- life                     : 3 - 4 hours 
 
Category                   :     Antibiotic 
M.O.A :  Cefixime binds to specific penicelline binding protein (PBPs) located 
iniside the bacterial cell wall causing the inhibition of the third and last 
stage of bacterial cell wall synthesis, whiche final transpeptiation step 
of the peptidoglycan synthesis in the bacterial cell wall. Thus 
inhibiting biosynthesis and arresting cell wall assembly resulting in 
bacterial cell death. 
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Adverse reaction :   Diarrhoea & abdominal pain 
• Headache 
• Nausea 
• Allergic reaction 
• It is not recommended history of severe  
    penicilline  allergy 
• Urticaria 
• Dizziness, 
• Loose stools 
      Dose   :   100 mg/5mL 
Pharmacokinetics 
Cefixime is an orally active cephalosporin antibiotic which has in-vitro bactericidal against a wide 
variety of Gram-positive and Gram-negative organisms including Streptococcus pneumonia, 
Streptococcus pyrogens, Escherichia coli, Proteus mirabilis, Klebsiella species, Haemophilus 
influenzae, (beta-lactamase positive and negative), Moraxella (Branhamella) catarrhalis (beta-
lactamase positive and negative). Cefixime is stable in the presence of beta-lactamase enzymes. 
Most strains of enterococci (Streptococcus faecalis, group D Streptococcus) and staphylococci 
(including coagulase positive and negative strains andmethicillin resistant strains) are resistant to 
cefixime. In addition, most strains of Enterobacter and Pseudomonas, bacteroides fragilis, Listeria 
monocytogenes and Clostridia are resistant to cefixime.      
 Pharmacodynamics 
 Cefixime an a antibiotic, is a third generation of cephalosporin group cefixme is  highly stable in 
the presence of beta-lactamase enzymes its inhibition mucopeptide  synthesis in the bacterial cell 
wall  
Uses : common cold, flu 
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6. MATERIALS AND INSTRUMENTS 
Instruments used: 
 System              : HPLC Agilent-2695 infinity 
 Pump                : I80 ( LC – 10 AT Vp series) 
 Detector            : UV/Visible E2469 
 Column             : Novapak C 18 column. (150mm x 3.9 mm, 4 µ )  
 pH meter           : Elico 
 Digital balance  : Sartorious BSA224S-CW 
 Sonicator           : PCI Analytics 
Reagents and Chemicals 
 Acetonitrile                                      :   HPLC grade(Merck) 
 Water                                               :   HPLC grade(MilliQ)  
 Ortho phosphoric acid                      :   AR grade(Merck)  
 Potassium dihydrogen phosphate    :  AR grade(Merck) 
 Tetra butyl ammonium hydroxide   :  AR grade(Merck) 
                    solution (40% in water)  
      
Reference Standards and sample 
1.  Cefixime purity                           :    89.0 % 
            2.   Oral suspension Brand Used       :   Supraxime oral suspension 
            3.    Label claim of Cefixime             :   100 mg/5mL  
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7. METHOD DEVELOPMENT AND OPTIMIZATION OF CHROMATOGRAPHIC    
CONDITIONS 
SOLUBILITY 
According to literature, Cefixime Soluble in methanol and in propylene glycol; slightly  soluble 
in alcohol, in acetone, and in glycerin; very slightly soluble in 70% sorbitol and in octanol; 
practically in soluble in ether, in ethyl acetate, in                                                                        
hexane, and in water. 
SELECTION OF CHROMATOGRAPHIC CONDITION 
The drugs selected in the present study are polar in nature and hence reversed phase or ion-pair 
or ion exchange chromatography method may be used. The reversed phase HPLC was selected 
for the separation because of its simplicity and suitability.  
SELECTION OF WAVELENGTH (λ max) 
In setting up the conditions for the development of the related substances method, the choice of 
detection wavelength was based on the scanned absorption for Cefixime. The spectrum was 
scanned over the range of 190 – 400nm and was obtained by measuring the absorption of 1.0 
mg/ml solution of Cefixime in methanol  and water prepared from stock solution. The spectrum 
was obtained by using HPLC. λ max of  cefixime  was 254. Hence for estimation 254 nm was 
selected. It shown in  (fig no :1 )                                                                                   
Spectrum of cefixime figure no: 1              
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7.1. METHOD DEVELOPMENT TRIALS 
Trial –1 
Preparation of Buffer Mobile Phase A:   
Mix 33 mL of Tetra butyl ammonium hydroxide solution (40% in water) in 1000 ml of water. 
Adjust the pH to 6.5 using orthophosphoric acid. Filter through 0.45µ membrane filter. 
Preparation of Mobile phase B: Acetonitrile. 
Diluent : Methanol and water 
Mobile phase Composition : Mobile phase A : Mobile phase B                                                                                              
35                                        80     :        20            
 The trail 1 was performed in the mobile phase of mobile phase A and mobile phase B in the 
ratio of  80 : 20 with the flow rate of 1 ml/min by using the C18 Novapak  150x3.9mm, 4 µ 
column and column temperature 40°C 
Result:  While injecting the above chromatographic condition, Analyte  peaks RT was found 
identified separately.  
Chromatogram no  : 1    
                       Trial  : 1 
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Trial –2  
Preparation of Buffer Mobile Phase A:   
Mix 33 mL of Tetra butyl ammonium hydroxide solution (40% in water) in 1000 ml of water. 
Adjust the pH to 6.5 using orthophosphoric acid. Filter through 0.45 µ membrane filter. 
Preparation of Mobile phase B: Acetonitrile. 
Diluent : Methanol and water 
Mobile phase Composition : Mobile phase A :  Mobile phase B                                                                                                               
35                                                 85    :   15               
The trail 2 was performed in the mobile phase of Mobile phase A and Mobile phase B  in the 
ratio of  85 : 15 with the flow rate 1.0 ml/min C18 Novapak  150x3.9mm, 4um column and 
column temperature 40°C 
Result:   While injecting the above chromatographic condition, the impurities  was merged with 
analyte  peak ,  Diluent and mobile phase ratio should not be shoutable, 
Chromatogram no   : 2 
                       Trial   :  2 
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TRIAL - 3             
Preparation of Buffer Mobile Phase A:   
Mix 33 mL of Tetra butyl ammonium hydroxide solution (40% in water) in 1000 ml of water. 
Adjust the pH to 6.5 using orthophosphoric acid. Filter through 0.45 µ membrane filter. 
Preparation of Mobile phase B: Acetonitrile. 
Diluent : potassium dihydrogen phosphate 0.1M adjust the PH-6.5 using with disodium Hyrogen 
phosphate 0.1M 
Mobile phase Composition : Mobile phase A : Mobile phase B                                 
35                                                          90      :    10               
The trail 3 was performed in the mobile phase of Mobile phase A and Mobile phase B in the 
ratio of  90:10 with the flow rate of 1.0 ml/min C18 Novapak  150 x 3.9mm, 4um column and 
column temperature 40°C 
  Result:   While injecting the above chromatographic condition, the impurities  was merged 
with analyte  peak  so it preferable to gradient programme 
 Chromatogram no  :  3    
                        Trial  : 3 
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TRIAL –4 
Preparation of Buffer Mobile Phase A:   
Mix 33 mL of Tetra butyl ammonium hydroxide solution (40% in water) in 1000 ml of water. 
Adjust the pH to 6.5 using orthophosphoric acid. Filter through 0.45 µ membrane filter. 
Mobile phase B: Acetonitrile. 
Diluent : potassium dihydrogen phosphate 0.1M adjust the PH-7.0 using with disodium Hyrogen 
phosphate 0.1M   
Chromatographic condition the flow rate of 1.0 ml/min C18 Novapak  150 x 3.9mm, 4um column 
and column temperature 40°C 
                                                          Gradient program 
Time Mobile phase A Mobile phase B 
0 90 10 
15 90 10 
50 65                    35 
52 90 10 
60 90 10 
 
Result:  
The cefixime was separated with impurity peak but very less value resolution should be 
produced so need to slightely changes to be gradient program 
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Chromatogram no   : 4   
                       Trial   : 4 
 
 
 
 
 
 
TRIAL –5 
Preparation of Buffer Mobile Phase A:   
Mix 33 mL of Tetra butyl ammonium hydroxide solution (40% in water) in 1000 ml of water. 
Adjust the pH to 6.5 using orthophosphoric acid. Filter through 0.45 µ membrane filter. 
Mobile phase B: Acetonitrile. 
Diluent : potassium dihydrogen phosphate 0.1M adjust the pH-7.0 using with disodium Hyrogen 
phosphate 0.1M,   
                                                          Gradient program 
Time Mobile phase A Mobile phase B 
0 90 10 
15 90 10 
50 70                     30 
52 90 10 
60 90 10 
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Result:  
The above mentioned method, Cefixime RT and all placebo RT and Blank were separated from 
main peak. impurities detected and separated with another impurities. 
 Chromatogram   : 5  
               Trial       : 5 
 
 Chromatograph conditions 
Column  : Novapak  C18, 150 X 3.9 mm, 4 µm  
Flow rate  : 1.0 ml / minute 
Injection volume : 10 µl 
Detector Wave length : 254 nm  
Column temperature : 40°C 
Run time                      : 60 min 
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Gradient program 
Time (min) A (%) B (%) 
0 90 10 
15 90 10 
50 70 30 
52 90 10 
60 90 10 
 
Preparation of Buffer: 
Mix 33 mL of Tetrabutyl ammonium hydroxide solution (40% in water) in 1000 ml of water. 
Adjust the pH to 6.5 using orthophosphoric acid. Filter through 0.45 µ membrane filter. 
Preparation of mobile phase: 
Mobile Phase  A : Buffer 
Mobile Phase  B : Acetonitrile 
Preparation of Solution A: 
Dissolve 6.8g of monobasic potassium phosphate  in water to make 500 ml of  miliq water and 
filter through 0.45um membrane filter 
Preparation of Diluent:  
Dissolve 7.1 g of anhydrous dibasic sodium phosphate in water to make 500 ml of solution. 
Adjust a volume of this solution with a sufficient volume of monobasic potassium phosphate 
(Solution A) solution to a pH of 7.0. 
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Preparation of system suitability solution: 
Weigh accurately and transfer about 25.0 mg of Cefixime working standard into a 25 mL 
volumetric, dissolve and dilute to the volume with mobile phase. Heat this solution on water bath 
for 45 minutes (In situ preparation of Cefixime E-isomer), cool and use.  
Preparation of standard stock solution: 
Weigh accurately and transfer about 25.0 mg of Cefixime working standard into a 25 mL 
volumetric, dissolve and dilute to the volume with mobile phase.   
Preparation of standard solution: 
Pipette out 1 mL of standard stock solution into a 100 mL volumetric flask and dilute to volume 
with mobile phase (Conc.:10 ppm  of cefixime). 
Placebo solution: 
Reconstitute the placebo with water. Weigh accurately the reconstituted placebo solution 
(equivalent to 100 mg of cefixime) into a 100 mL volumetric flask. Dilute to volume with diluent 
and mix well. Centrifuge this solution at 2500 RPM for 10 mins. Use the supernatant solution.  
Sample solution: 
Reconstitute the sample upto the mark with water. Weigh accurately the reconstituted solution 
(equivalent to 100 mg of cefixime) into a 100 mL volumetric flask. Dilute to volume with diluent 
and mix well. Centrifuge this solution at 2500 RPM for 10 mins. Use the supernatant solution. 
(Conc.: 1000 ppm  of cefixime) 
Procedure 
Inject 10 µl of diluent as blank, System suitability solution, Standard solution, placebo solution 
and sample solution into the chromatograph, record the chromatogram and measure the peak 
response. The related sequence as mentioned below table. 
 
Chapter 7                                                                                                                                      Method development 
 
 Department Of Pharmaceutical Analysis              48                  J.K.K. Nataraja College Of Pharmacy 
 
 
Name of the Solution Number of Injection 
Blank (Diluent) 1 
System suitability solution 1 
Standard Solution  5 
Placebo solution 1 
Sample Solution  1 
Standard Solution (Bracketing standard ) 1 
 
Note: Inject bracketing standard after every six injections of the test preparation or end of the 
sequence. The area difference between each bracketing standard and average area of standard 
preparation should be with in ±2.0%. 
Evaluation of system suitability: 
1. The resolution between Cefixime and Cefixime E-isomer peaks from system suitability 
solution should not be less than 2.0. 
2. % RSD for five replicate injections of standard  solution should not be more than 2.0. 
Related Substance Of Proposed Method: 
Procedure:   
                   Separately inject both the standard and sample preparations  into liquid 
chromatogram and record the peak area responses.  The % RSD is not more than 2.0. 
Calculation 
Note: Disregard the peaks with area % less than 0.05% and the peaks due to blank and placebo. 
Calculate the percentage of individual impurities in the portion of Cefixime for oral suspension 
taken as follows: 
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                                     At X Ws X1 X100 X P X d X D X 100    
% of individual Imp= ----------------------------------------------------------- 
                                      As X 25 X 100 X W X 100 X L   
% of total imp = Sum of % of all individual impurities 
Where, 
At =  Peak response for individual impurity from the test solution 
As =  Average Peak response for cefixime from the standard solution  
Ws =  Standard weight in mg  
d =  Weight per ml (Density) of the oral suspension in mg  
W =  Weight of oral suspension taken in mg 
L =  Label claim in mg 
P =  Purity in as such basis 
D         =  Dose, 5 ml 
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                             8. VALIDATION OF RP-HPLC METHOD 
        After development of HPLC method for the estimation of the Single 
component dosage forms validation of the method was carried out. This section 
describes the procedure followed for the validation of the developed method. 
8.1 SOLUTION STABILITY 
Performed the solution stability of standard and test preparation as per the given the 
method of analysis. Kept the standard preparation and test preparation on bench top 
analyse initially and different time intervals up to 24 hrs. Calculated the % 
difference of impurities in sample solution and the % RSD for standard solution 
response, tabulatet the results in the table given below.Its shown chromatogram 
no:(1-2) 
Table no:1  Solution stability impurity values  given below the table 
 
Time 
in 
hours 
E- isomer Highest unknown 
Impurity Total Impurities 
% 
Impurity 
% 
Difference 
from 
Initial 
% 
Impurity 
% 
Difference 
from 
Initial 
% 
Impurity 
% 
Difference 
from 
Initial 
Initial 0.084 NAP 0.468 NAP 2.06 NAP 
4 0.086 2.4 0.462 1.3 2.10 1.9 
8 0.086 2.4 0.457 2.4 2.21 7.6 
12 0.093 10.7 0.438 6.4 2.35 14.3 
16 0.093 10.7 0.466 0.4 2.50 21.5 
20 0.094 11.9 0.478 -2.1 2.62 27.3 
24 0.085 1.2 0.437 6.6 2.60 26.5 
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Table no :2 Solution stability values given below 
 
Acceptance Criteria 
1. The difference between initial and bench top stability sample for % of known 
impurity, Highest unknown impurity and Total Impurities should be ±15.0 
%. 
2. The% RSD of peak responses between initial and bench top stability for 
diluted standard not more than 2.0. 
Conclusion          
The % RSD of peak area of standard solution from initial to 24 Hours was found 
within the limits. The % difference of % of impurity for sample solution is failing at 
16 th Hour. From the above study, it was established that the Standard solution is 
stable for a period of about 24 Hours and sample solution is stable for a period of 
about 12 Hours at bench top. 
 
Time in hours Response of standard solution   
Initial 2842486 
4 th Hour 2854792 
8 th Hour 2791283 
12 th Hour 2852277 
16 th Hour 2824500 
20 th Hour 2807373 
24 th Hour 2827914 
Mean 2828785 
SD 25687.314 
% RSD 0.9 
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8.2 SYSTEM SUITABILITY STUDIES 
           System suitability studies were carried out as specified in the United States 
Pharmacopoeia (USP). These parameters include column efficiency, resolution, 
tailing factor and RSD were calculated in present study. 
Prepared Standard Preparations as per test procedure and made six replicate 
injections. Evaluated system suitability parameters as per the test procedure and 
tabulated the results in the table given below. Its shown chromatogram no:(3) 
Table no:3   System suitability parameters 
System Suitability Parameters Observed value Acceptance 
criteria 
Resolution between Cefixime and Cefixime 
(E)-isomer obtained from  system suitability 
solution 
3.0 NLT 2.0 
The relative standard deviation obtained 
from  six replicate injections of standard 
solution  
0.7 NMT 2.0 
Table no: 4  Response of the Standard replicate injections 
No of injection 
Response 
Cefixime 
01 355423 
02 351334 
03 350899 
04 352759 
05 352560 
06 357365 
Mean 353390 
Stdev. 2508.107 
% RSD 0.7 
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Acceptance criteria:  
1. The resolution between Cefixime and Cefixime E-isomer peaks from system 
suitability solution is not less than 2.0. 
2. % RSD for six replicate injections of standard  solution should not be more 
than 2.0. 
Conclusion: The System suitability parameters are within the limit. 
8.3 SPECIFICITY 
 The following methods were employed for demonstrating specificity for 
HPLC method. In the first method, the conditions of HPLC method developed, 
namely, percentage of the organic solvent in mobile phase, pH of the mobile phase, 
flow rate, etc. were changed in HPLC and the presence of additional peaks, if any, 
was observed. The second method involves the peak purity test method using diode 
array detector. The diode array derivative spectrums and derivative chromatograms 
of the standard and sample drug peaks were recorded and compared. The third 
method was based on measurement of the absorbance ratio of the drug peaks at 
different wavelengths Its shown chromatogram no:(4-8). 
Placebo interference 
Specificity is the ability of the method to measure the analyte in the presence of 
matrix components. The Specificity will be demonstrated by injecting the solutions 
of blank, placebo mixture, standard and sample solution. The interference with 
placebo mixture is checked. 
Table no: 5 Summarized  the results in the Cefixime table given below. 
Sample ID 
Interference (Cefixime) 
RT (min) Peak purity  
Blank Nil NA 
Placebo  Nil NA 
Standard with placebo 
solution 
32.22 1.0 
Standard solution 32.83 1.0 
Test Sample  32.49 1.0 
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Table no: 6 Summarized  the results in the Cefixime E-isomer table given below 
Sample ID 
Interference (Cefixime E-isomer) 
RT (min) Peak purity  
Blank Nil NA 
Placebo  Nil NA 
Standard with placebo 
solution 
30.27 1.0 
Test Sample  30.53 1.0 
 
Acceptance Criteria 
1. There should not be any interference of blank, placebo peaks at the Retention 
Time (RT) of main peak and known impurity peaks. 
2. The Peak Purity should be not less than 0.9 in open lab software / purity 
angle should less than purity threshold for Empower Software. 
Conclusion  
The above observation reveals that no interference of any of the blank and placebo 
was observed at the retention time (RT) of main peak and known impurity peaks. 
8.4 LIMIT OF DETECTION (LOD)  
            Limit of detection is the lowest concentration of the analyte that can be 
detected by injecting decreasing amount, not necessarily quantity by the method, 
under the stated experimental conditions. The minimum concentration at which the 
analyte can be detected is determined from the linearity curve by applying the 
formula. 
                                                              σ 
             Limit of detection     =                       X  3.3          
                                                              S           
LIMIT OF QUANTITATION  (LOQ ) 
           Limit of Quantitation is the lowest concentration of the analyte in a sample 
that can be estimated quantitatively. By injecting decreasing  amount of drug, with 
acceptable precision and accuracy under the experimental conditions of the method. 
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Limit of Quantitation can be obtained from linearity curve by applying the following 
formula. 
                                                         σ 
          Limit of Quantitation   =              X10 
                                                          S   
Limit Of Detection and Limit Of Quantitation 
Prepared and injected different concentration of Cefixime (0.01 % to 0.06% of 
working concentration) from standard stock solution and determined the LOD, LOQ 
by residual standard deviation method. Results are summarized in the below table. 
Its shown chromatogram no:(9-10) 
Table no: 7  LOD and LOQ  values  given below 
Sr. no. Level (%) 
Concentration in µg/ml 
(ppm) Cefixime Response of Cefixime peak 
01 0.01 0.1 6619 
02 0.02 0.2 9462 
03 0.03 0.3 13959 
04 0.04 0.4 15808 
05 0.05 0.5 17448 
06 0.06 0.6 19303 
σ (standard deviation) 1035.787 
Slope 25493.43 
 
Table no: 8  Result of  LOD and LOQ  values  given below 
 
LOD LOQ 
% with respect to test 
concentration ppm 
% with respect to test 
concentration ppm 
0.01 0.1 0.04 0.4 
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Precision at LOD and LOQ: 
Injected LOD and LOQ solution (6 replicates), Calculated percentage RSD. The 
results are summarized in the table given below. 
 
Table no: 9  Precision of  LOD and LOQ  values  given below 
 
No of Injection LOD LOQ 
01 8034 15432 
02 8515 15069 
03 5952 15078 
04 6811 15889 
05 6999 15357 
06 4904 15347 
Mean 6869 15362 
Stdev. 1325.814 299.795 
% RSD 19.3 2.0 
 
Acceptance criteria 
1. The % Relative standard deviation for six replicate LOD level areas should 
be NMT 30.0%. 
2. The % Relative standard deviation for six replicate LOQ level areas should 
be NMT 10.0%. 
 
Conclusion: 
The Relative Standard Deviation for Limit of Detection and Relative Standard 
Deviation results for limit of quantification were found within limits.  
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8.5 LINEARITY & RANGE 
Ability (within a given range) to obtain test results which are directly proportional to 
the concentration (amount) of analyte in the sample. Performed the linearity in the 
concentrations at LOQ, 50%, 75%, 100%, 125%, 150% , 175% and 200% of 
specification limit. Recorded the area for each level and calculate slope, y- intercept 
& coefficient of correlation and coefficient of regression. Plotted the graph of 
Cefixime concentration on X- axis and area response on Y-axis. Summarized  the 
results in the below table. Its shown chromatogram no:(11-14) 
Table no: 10 Linearity of the sample calculation given below 
Sr. No. % Level  Concentration in µg/ml (ppm) Peak Response of Cefixime 
01 LOQ 0.4 10371 
02 50 10 338460 
03 75 15 518872 
04 100 20 697549 
05 125 25 881632 
06 150 30 1043549 
07 200 40 1399437 
Slope 35170.1295 
Y intercept  -6859.4550 
Coefficient of correlation  0.9999 
Coefficient of regression 0.9999 
Y intercept should be ± 5.0% of the active response 
at 100% concentration 1.0 
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Fig no : 2 Linearity of Cefxime 
 
 
 
 
 
 
 
 
 
(fig : 2) 
Acceptance Criteria: 
1. The Coefficient of correlation should not be less than 0.995. 
2. The Y intercept should be ± 5.0% of the active response at 100% concentration. 
 
Conclusion  
The detector response was found linear with a Coefficient of correlation of 0.9999 
and Coefficient of regression 0.9999 for Cefixime shows that the related substances 
method was meeting the linearity and range acceptance criteria. 
  
8.6 ACCURACY 
Accuracy of the method was determined by recovery experiments. To the formulation, the 
reference standards of the respective drugs were added at the level of 100 %. These were 
further diluted by procedure as followed in estimation of formulation. The resulting sample 
solutions were analyzed by HPLC. The amount of the each drug present, percentage 
recovery, percentage relative standard deviation (% RSD) was calculated. The percentage 
recovery was calculated using the formula, 
 Percentage recovery 100][ x
b
aba −+
=
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Accuracy is the closeness of the test results obtained by the method to the true value. 
Accuracy may often be expressed as percent recovery by the assay of known, added 
amounts of analyte. Accuracy is a measure of the exactness of analytical method. 
Injected triplicate preparations by spiking Cefixime on placebo from LOQ, 50%, 
100%, 150% and 200% with respect to target concentration. Calculated the % 
Recovery for Cefixime. Summarized the results in the table given below. Its shown 
chromatogram no:(15-18) 
Table no: 11 Accuracy of the product in the table given below 
Series 
No of 
Sample 
Added in 
ppm Found in ppm 
Recovery in 
% 
Average in 
% 
LOQ 
01 0.401 0.398 99.3 
98.1 02 0.401 0.388 96.8 
03 0.401 0.393 98.1 
50% 
01 10.020 10.075 100.5 
100.9 02 10.020 10.169 101.5 
03 10.020 10.105 100.8 
100% 
01 20.040 20.029 99.9 
98.8 02 20.040 20.042 100.0 
03 20.040 19.359 96.6 
 
150% 
01 30.060 29.288 97.4 
98.9 02 30.060 30.206 100.5 
03 30.060 29.689 98.8 
 
200% 
01 40.080 37.962 94.7 
95.0 02 40.080 36.644 91.4 
03 40.080 39.598 98.8 
 
Mean 98.5 
 
Stdev. 2.431 
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% RSD 2.5 
 
 Acceptance Criteria  
1. The % Recovery at 50 % to 200% level should not be less than 90.0% and 
not more than 110.0%. 
2. The % Recovery at LOQ level should not be less than 80.0% and not more 
than 120.0%. 
Conclusion: 
The % Recovery for Cefixime (unknown impurity) were found within the limits. 
Comparison of above results meeting the accuracy acceptance criteria. 
 
8.7 PRECISION  
• Method Precision (Repeatability) 
To demonstrate the method precision of the related substances method by analyzing 
six replicates of sample preparation. Calculated the mean value, the standard 
deviation and the relative standard deviation for known impurity, Highest unknown 
impurity and Total Impurities. Summarized the results in the table given below. Its 
shown chromatogram no:(19-20)  
 Table no: 12  Repeatability of the product results in the table given below 
 
No. of Sample  
Method Precision  
E- Isomer Highest unknown impurity 
Total 
Impurities 
RRT % RRT % % 
01 0.94 0.10 1.07 0.31 1.84 
02 0.94 0.10 1.07 0.30 1.81 
03 0.94 0.10 1.07 0.29 1.51 
04 0.94 0.09 1.07 0.29 1.73 
05 0.94 0.08 1.07 0.29 1.66 
06 0.94 0.10 1.07 0.28 1.74 
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Mean 
 
0.09 
 
0.29 1.72 
SD 0.006 0.011 0.119 
% RSD 6.5 3.7 6.9 
 
Acceptance Criteria 
 The % RSD of known impurity, Highest unknown impurity and Total Impurities 
should not be more than 10.0. 
Conclusion  
The % RSD of % of known impurity, highest unknown impurity and total impurities 
obtained from six preparations of sample solution were found within the limits. 
• Intermediate precision   
Performed the procedure as detailed in the method precision study on a different 
day, by a different analyst, preferably using a different instrument and with freshly 
prepared mobile phase, sample and standard preparation. Prepared the test solution 
in replicate (six Preparations) using the same batch, which is taken for method 
precision, study.  
Calculated the mean value, the standard deviation, the relative standard deviation for 
known impurity, Highest unknown impurity and Total Impurities. Summarized the 
results in the table given below Its shown chromatogram no:(21-22) 
Table no: 13 Intermediate precision of the product results in the table given 
below 
 
No. of Sample  
Intermediate Precision  
E- Isomer Highest unknown impurity 
Total 
Impurities 
RRT % RRT % % 
01 0.94 0.09 1.07 0.31 1.52 
02 0.94 0.09 1.07 0.32 1.44 
03 0.94 0.09 1.07 0.31 1.41 
04 0.94 0.09 1.06 0.32 1.52 
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05 0.96 0.09 1.06 0.30 1.51 
06 0.94 0.08 1.06 0.31 1.52 
Mean 
 
0.09 
 
0.31 1.49 
SD 0.003 0.006 0.048 
% RSD 4.0 1.9 3.2 
 
Table no: 14 Comparison of method precision and intermediate precision 
results: 
 
No. of Sample  
Overall % RSD  
E- Isomer Highest unknown Impurity 
Total 
Impurities 
RRT % RRT % % 
Method 
precision  
01 0.94 0.10 1.07 0.31 1.84 
02 0.94 0.10 1.07 0.30 1.81 
03 0.94 0.10 1.07 0.29 1.51 
04 0.94 0.09 1.07 0.29 1.73 
05 0.94 0.08 1.07 0.29 1.66 
06 0.94 0.10 1.07 0.28 1.74 
Intermediate 
precision 
07 0.94 0.09 1.07 0.31 1.52 
08 0.94 0.09 1.07 0.32 1.44 
09 0.94 0.09 1.07 0.31 1.41 
10 0.94 0.09 1.06 0.32 1.52 
11 0.96 0.09 1.06 0.30 1.51 
12 0.94 0.08 1.06 0.31 1.52 
Overall Mean (n=12) 
 
0.09 
 
0.30 1.60 
SD 0.006 0.013 0.147 
Chapter  8                                                                               Validation of RP-HPLC method 
 Department of pharmaceutical Analysis             63      J.K.K. Nataraja College of Pharmacy    
 
% RSD 6.8 4.3 9.2 
 
Acceptance Criteria    
1. The % RSD of known impurity, Highest unknown impurity and Total 
Impurities should not be more than 10.0. 
2. The over all % RSD of known impurity, Highest unknown impurity and 
Total Impurities obtained from method precision and intermediate precision 
results should not be more than 10.0.                                                                                            
Conclusion:                                                                                                                                                                               
The % RSD of % of known impurity, Highest unknown impurity and Total 
Impurities obtained from six preparations of sample solution were found within the 
limits. Comparison of the results obtained by two different days with different 
analysts and different instruments, shows that the related substances method was 
meeting the Intermediate precision acceptance criteria. 
8.8 ROBUSTNESS  
The robustness of an analytical method is a measure of its capacity to remain 
unaffected by small but deliberate variations in method parameters and provides an 
indication of its reliability during normal usage. 
In order to demonstrate the robustness of the method, the following 
optimized conditions were slightly varied. The separation factor, retention times and 
peak symmetry were then calculated. 
• Effect of variation in column oven temperature 
To demonstrate the robustness of test method, prepared and injected standard 
solution and sample solution at 35°C and at 45°C of column oven temperature. 
Calculated the overall % RSD for known impurity, highest unknown impurity and 
total impurity obtained from method precision and robustness results. Summarized 
the results in the below table. Its shown chromatogram no:(23-24) 
Table no: 15 Robustness system suitability values of  Colum temperature  
variation 
 
System Suitability 
Parameters 
Observed value with 
Column temperature 
 
Acceptance 
criteria 
 
35°C 40°C 45°C 
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Resolution between Cefixime and Cefixime 
(E)-isomer obtained from  system suitability 
solution 
4.3 3.0     3.9 NLT 2.0 
The relative standard deviation obtained from  
five replicate injection standard  solution  1.5 0.7     1.3 NMT 2.0 
 
Table no: 16  Robustness  values of  Low column oven temperature (35°C) 
 
No. of Sample  
Overall % RSD 
E-isomer 
Highest 
unknown 
Impurity 
Total 
treImpurities 
RRT % RRT % % 
Method 
precision  
01 0.94 0.10 1.07 0.31 1.84 
02 0.94 0.10 1.07 0.30 1.81 
03 0.94 0.10 1.07 0.29 1.51 
04 0.94 0.09 1.07 0.29 1.73 
05 0.94 0.08 1.07 0.29 1.66 
06 0.94 0.10 1.07 0.28 1.74 
Robustness 
 
07 0.9 0.079 1.1 0.338 1.60 
08 0.9 0.08 1.1 0.306 1.62 
Overall Mean (n=8) 
 
0.09 
 
0.30 1.69 
SD 0.01 0.02 0.11 
% RSD 9.20 6.34 6.67 
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Table no: 17  Robustness  values of  High column oven temperature (45°C) 
 
No. of Sample  
Overall % RSD 
E-isomer 
Highest 
unknown 
Impurity  
Total 
Impurities 
RRT % RRT % % 
Method 
precision  
01 0.94 0.10 1.07 0.31 1.84 
02 0.94 0.10 1.07 0.30 1.81 
03 0.94 0.10 1.07 0.29 1.51 
04 0.94 0.09 1.07 0.29 1.73 
05 0.94 0.08 1.07 0.29 1.66 
06 0.94 0.10 1.07 0.28 1.74 
Robustness 
 
07 0.9 0.11 1.1 0.27 1.63 
08 0.9 0.09 1.1 0.26 1.61 
Overall Mean (n=8) 
 
0.10 
 
0.28 1.69 
SD 0.01 0.02 0.11 
% RSD 8.51 5.65 6.49 
 
Acceptance criteria:   
The over all % RSD of Known impurity, Highest unknown Impurity and Total 
Impurities obtained from method precision and robustness results should not be 
more than 10.0. 
Conclusion: 
The overall % RSD of % of known impurity, Highest unknown impurity and Total 
Impurities obtained from method precision and robustness results meeting the 
acceptance criteria. The above study indicates that column oven temperature from 
35°C to 45°C is suitable. 
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• Effect of variation in flow rate  
To demonstrate the robustness of test method, prepared and injected standard 
solution and sample solution at 0.8 mL/min and at 1.2 mL/min of flow rate. 
Calculated the overall % RSD for known impurity, highest unknown impurity and 
total impurity obtained from method precision and robustness results. Summarized 
the results in the below table Its shown chromatogram no:(25-26) 
Table no: 18  Robustness system suitability values of flow rate variation  
 
System Suitability 
Parameters 
Observed value with 
Flow rate 
 
Acceptance 
criteria 
 
0.8 
mL 
/min 
1.0 
mL/min 
1.2 
mL/min 
Resolution between Cefixime 
and Cefixime (E)-isomer 
obtained from  system suitability 
solution 
3.0 3.0 3.2 NLT 2.0 
The relative standard deviation 
obtained from  five replicate 
injections of standard solution  
0.5 0.7 0.6 NMT 2.0 
 
     Table no: 19 Robustness  values of  Low flow rate(0.8ml/min) 
 
No. of Sample  
Overall % RSD 
E-isomer 
Highest 
unknown 
Impurity  
Total 
Impurities 
RRT % RRT % % 
Method 
precision  
01 0.94 0.10 1.07 0.31 1.84 
02 0.94 0.10 1.07 0.30 1.81 
03 0.94 0.10 1.07 0.29 1.51 
04 0.94 0.09 1.07 0.29 1.73 
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05 0.94 0.08 1.07 0.29 1.66 
06 0.94 0.10 1.07 0.28 1.74 
Robustness 
 
07 0.94 0.085 1.07 0.313 1.81 
08 0.94 0.087 1.07 0.337 1.81 
Overall Mean (n=8) 
 
0.09 
 
0.30 1.74 
SD 0.01 0.02 0.11 
% RSD 6.80 6.41 6.31 
 
Table no: 20 Robustness  values of  High flow rate(1.2ml/min) 
 
No. of Sample  
Overall % RSD 
E-isomer 
Highest 
unknown 
Impurity  
Total 
Impurities 
RRT % RRT % % 
Method 
precision  
01 0.94 0.10 1.07 0.31 1.84 
02 0.94 0.10 1.07 0.30 1.81 
03 0.94 0.10 1.07 0.29 1.51 
04 0.94 0.09 1.07 0.29 1.73 
05 0.94 0.08 1.07 0.29 1.66 
06 0.94 0.10 1.07 0.28 1.74 
Robustness 
 
07 0.93 0.089 1.07 0.246 1.89 
08 0.93 0.088 1.07 0.248 1.99 
Overall Mean (n=8) 
 
0.09 
 
0.28 1.77 
SD 0.01 0.02 0.15 
% RSD 6.13 8.03 8.31 
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Acceptance criteria:   
The over all % RSD of known impurity, highest unknown impurity and total 
impurity obtained from method precision and robustness results should not be more 
than 10.0. 
Conclusion: 
The overall % RSD of % of known impurity, Highest unknown impurity and Total 
Impurities obtained from method precision and robustness results meeting the 
acceptance criteria. The above study indicates that flow rate from 0.8mL/min to 1.2 
mL/min is suitable. 
• Effect of variation in mobile phase pH 
To demonstrate the robustness of test method, prepared and injected standard 
solution and sample solution at pH of 6.3 and 6.7 of mobile phase pH. Calculated 
the overall % RSD for known impurity, highest unknown impurity and total 
impurity obtained from method precision and robustness results. Summarized the 
results in the below table. Its shown chromatogram no:(27-28) 
Table no: 21  Robustness system suitability  values  mobile phase pH variation  
 
System Suitability 
Parameters 
Observed value with pH  
Acceptance 
criteria 
 
6.3 6.5 6.7 
Resolution between Cefixime and Cefixime 
(E)-isomer obtained from  system suitability 
solution 
4.12 3.0 4.3 NLT 2.0 
The relative standard deviation obtained 
from  five replicate injections of standard 
solution  
0.74 0.7 0.87 NMT 2.0 
 
Table no: 22  Robustness mobile phase Low  pH (6.3)  values 
 
 
No. of Sample 
Overall % RSD 
E-isomer 
Highest 
unknown 
Impurity 
Total 
Impurities 
RRT % RRT % % 
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Method 
precision 
01 0.94 0.10 1.07 0.31 1.84 
02 0.94 0.10 1.07 0.30 1.81 
03 0.94 0.10 1.07 0.29 1.51 
04 0.94 0.09 1.07 0.29 1.73 
05 0.94 0.08 1.07 0.29 1.66 
06 0.94 0.10 1.07 0.28 1.74 
Robustness 
 
07 0.94 0.318 1.07 0.318 1.76 
08 0.94 0.333 1.07 0.333 1.77 
Overall Mean (n=8) 
 
0.10 
 
0.30 1.73 
SD 0.01 0.02 0.10 
% RSD 7.65 6.25 5.99 
 
Table no: 23 Robustness mobile phase High pH (6.7)  values  
 
No. of Sample  
Overall % RSD 
E-isomer 
Highest 
unknown 
Impurity  
Total 
Impurities 
RRT % RRT % % 
Method 
precision  
01 0.94 0.10 1.07 0.31 1.84 
02 0.94 0.10 1.07 0.30 1.81 
03 0.94 0.10 1.07 0.29 1.51 
04 0.94 0.09 1.07 0.29 1.73 
05 0.94 0.08 1.07 0.29 1.66 
06 0.94 0.10 1.07 0.28 1.74 
Robustness 
 
07 0.94 0.089 1.07 0.257 1.72 
08 0.93 0.086 1.08 0.26 1.65 
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Overall Mean (n=8) 
 
0.10 
 
0.30 1.73 
SD 0.01 0.02 0.10 
% RSD 7.65 6.25 5.99 
 
Acceptance criteria:  The overall % RSD of known impurity, highest unknown 
impurity and total impurity obtained from method precision and robustness results 
should not be more than 10.0. 
Conclusion: 
The overall % RSD of % of known impurity, Highest unknown impurity and Total 
Impurities obtained from method precision and robustness results meeting the 
acceptance criteria.  
The above study indicates that mobile phase pH 6.3 to 6.7 is suitable. 
 
8.9 INTERFERENCE FROM DEGRADATION PRODUCTS 
A study was conducted to demonstrate the effective separation of degradants from 
Cefixime for oral suspension USP 100 mg/5mL of related substances method. Drug 
product, Placebo and Blank were exposed to the following stress conditions to 
induce degradation Its shown chromatogram no:(29-32) 
Table no:24 Degradation of the product in the table given below 
  Stress Condition 
Cefixime 
RT (min) % degradation Peak purity 
Kept in water bath  at 60°c with 5 mL 
of 5M HCl for 60 minutes (Acid 
Hydrolysis). 
32.65 19.41 1.00 
Kept in bench top with 5 mL of 0.5M 
NaOH for 5minutes (Base 
Hydrolysis). 
31.93 12.64 1.00 
Kept in bench top with 5 mL of 3% 
Hydrogen peroxide solution for 5 
minutes (Oxidation). 
31.92 5.86 1.00 
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Reconstituted sample was kept in 
room temperature for 24 hours (Water 
Hydrolysis). 
32.39 0.49 1.00 
Exposed to Dry heat at 50° C for about 
6 days. 32.28 0.04 1.00 
Exposed to humidity at 25°C and 90% 
RH for about 7 days. 32.29 0.07 1.00 
 
Acceptance Criteria: 
1. There should not be any interference of degradants at the Retention Time 
(RT) of main peak and known impurity peaks. 
2. The Peak Purity should be not less than 0.9 in open lab software / purity 
angle should less than purity threshold for Empower Software. 
 
Conclusion :  
The above observation reveals that no interference of  degradants was observed on 
the area of  Cefixime  and all impurities as well. This demonstrates that the method 
is specific for Related Substances of  Cefixime for oral suspension USP 100 
mg/5mL. 
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                             9. VALIDATION CHROMATOGRAM 
Chromatogram no: 1   
A Representative chromatogram of solution stability of Dilutes Standard 
Chromatogram no: 2 
A Representative chromatogram of solution stability Sample 
Chromatogram no: 3   
Representative chromatogram of  system suitability solution 
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Chromatogram no: 4  
A Representative Chromatogram of Specificity Blank  
  
Chromatogram no: 5  
A Representative Chromatogram of Specificity Placebo 
 
Chromatogram no: 6  
A Representative Chromatogram of Specificity System suitability 
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Chromatogram no: 7  
A Representative Chromatogram of  Specificity  Diluted standard 
 
Chromatogram no: 8 
A Representative Chromatogram of  Specificity Sample 
 
 
Chromatogram no: 9 
A Representative chromatogram of LOD concentration of  Cefixime 
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Chromatogram no: 10 
A Representative chromatogram of  LOQ concentration of  Cefixime 
Chromatogram no: 11 
A Representative chromatogram of the linearity 50% solution 
  
Chromatogram no: 12 
A Representative chromatogram of the linearity 100% solution 
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Chromatogram no: 13 
A Representative chromatogram of the linearity 150% solution 
Chromatogram no: 14 
A Representative chromatogram of the linearity 200% solution 
 
Chromatogram no: 15 
A Representative chromatogram of Accuracy sample 50 % 
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Chromatogram no: 16 
A Representative chromatogram of Accuracy sample 100 % 
 
Chromatogram no: 17 
A Representative chromatogram of Accuracy sample 150 % 
 
Chromatogram no: 18 
A Representative chromatogram of Accuracy sample 200 % 
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Chromatogram no: 19 
A Representative chromatogram of Precision Diluted standard 
Chromatogram no: 20 
A Representative chromatogram of Precision sample  
 
Chromatogram no: 21 
A Representative chromatogram of Intermediate Precision Diluted standard 
Chapter 12                                                                                Bibliography 
Chromatogram no: 22 
A Representative chromatogram Intermediate Precision sample 
Chromatogram no: 23 
A Representative chromatogram of Robustness low column temperature 
sample  
Chromatogram no: 24 
A Representative chromatogram of Robustness High column temperature 
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sample  
Chromatogram no: 25 
A Representative chromatogram of Robustness low flow rate sample 
Chromatogram no: 26 
A Representative chromatogram of Robustness High flow rate sample  
Chromatogram no: 27 
A Representative chromatogram of Robustness low pH sample 
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Chromatogram no: 28 
A Representative chromatogram of Robustness High pH sample 
Chromatogram no: 29 
Representative chromatogram of Acid stress sample 
Chromatogram no: 30 
Representative chromatogram of  Base stress sample 
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Chromatogram no: 31 
Representative chromatogram of peroxide stress sample 
 
Chromatogram no: 32 
Representative chromatogram of thermal stress sample 
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10.   RESULT AND DISCUSSION 
VALIDATION OF THE METHOD 
The  solution stability studies were carried out at zero hour and after 24 hour, results were 
tabulated in table (1 and 2) The suitability of the system was studied by the values obtained for 
Theoretical plate, Resolution and tailing factor, %RSD of the chromatogram of standard drugs 
and presented in the table(3 and 4). 
The selectivity of the method was revealed by the repeated injection of mobile phase and 
no interference was found and presented in Table (5 and 6) 
The LOD and LOQ were calculated for Cefixime , it was presented in Table (7,8 and 9) 
The limit of detection for cefixime  was found to be 0.1µg/ml. 
The Limit of Quantitation for cefixime was found to be 0.4µg/m 
The linearity of proposed method were performed by using the concentration range of 
LOQ to 200% of standard concentration i.e 0.1 µg/ml to 0.6 µg/ml of cefixime trihydrate  was 
presented in Table (10). The response factor, slope, intercept and correlation co-efficient were 
calculated. The slope, intercept, correlation co-efficient were found to be within the limit for 
cefixime  . The calibration curves were plotted using response factor (Vs) concentration of 
standard solutions (fig: 02). The calibration graph shows that linear response was obtained over 
the range of concentration used in the procedure. These data demonstrates that the method have 
adequate sensitivity to the analytes. The range demonstrate that the method is linear outside the 
limits of expected use. 
      The Accuracy of the method was determined by recovery experiments. The recovery studies 
were carried out by preparing 4 individual samples with same procedure from the formulation 
and injecting. The percentage recovery and percentage relative standard deviation of the 
percentage recovery was calculated and presented in Tables  (11). From the data obtained, added 
of standard drugs were found to be accurate. 
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The precision of the method was demonstrated by system and method precision. and 
intermediate precision of all solutions were injected into the chromatographic system performed   
by analyst 1 and analyst 2  The peak area and percentage relative standard deviation were 
calculated and presented in tables (12) & (13) ,The comparision of precision an intermediate 
precision presented in table (14)   
The robustness of the method was studied by carrying out experiments by changing 
conditions discussed earlier. The response factors for these changed chromatographic parameters 
were almost same as that of the fixed chromatographic parameters Table (15to23) and hence 
developed method is said to be robust and ruggedness .The degradation of stress study of the 
product calculation presented in Table (24) 
Validation protocal summary 
  
Parameter Experiment Observation Acceptance criteria 
 
Solution 
stability 
 
Bench top stability of 
standard  solution 
   24 hours 
 
  12 hours 
The difference between initial 
and bench top stability sample 
for %  of Relative standard 
deviation  known impurity and 
Highest unknown impurity 
Bench top stability of  
Test solution 
 
System 
suitability 
 
% RSD  Resolution 
 
      3.0 
 
System NLT 2.0 suitability 
parameter should    pass. 
 
 
 
 
Specificity 
 
 
Placebo and Blank, 
Impurity interference 
and Interference from 
Degradation products 
 
 
  Complies 
 
 
     1.0 
There should not be any 
interference of blank, placebo 
peaks at the Retention Time 
(RT) of main peak and known 
impurity peaks. 
The Peak Purity should be not 
less than 0.9 in open lab 
software / purity angle should 
less than purity threshold for 
Empower Software. 
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Limit Of 
Detection And 
Limit Of 
Quantitation 
 
 
Relative standard 
deviation method 
 
       19.3 % 
 
       2.0 % 
   
The % Relative standard 
deviation for six replicate LOD 
level areas should be NMT 
30.0%. 
The % Relative standard 
deviation for six replicate LOQ 
level areas should be NMT 
10.0%. 
 
Linearity and 
Range 
 
Coefficient of 
correlation ( r)  
 
        
      0.999 
 
     1.0 % 
 
The Coefficient of correlation 
should not be less than 0.995. 
The Y intercept shall be ± 5.0% 
of the active response at 100% 
concentration. 
 
 
 
Accuracy 
 
 
  % Recovery 
 
Complies 
 
 
Complies 
 
The % of  Recovery at 50 % to 
200% level should not be less 
than 90.0% and not more than 
110.0%. 
The % Recovery at LOQ level 
should not be less than 80.0% 
and not more than 120.0%. 
 
Precision 
 
 
Method Precision 
       6.5% 
 
3.7 %  
 
6.9 % 
 The % RSD of known 
impurity, 
Highest unknown impurity and  
Total Impurities should not be 
more than 10.0. 
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Intermediate          
Precision  
    
        4.0  % 
  
       1.9  % 
 
        
        3.2 % 
The % RSD of known 
impurity, 
Highest unknown impurity and 
Total Impurities should not be 
more than 10.0. 
The overall % RSD of known 
impurity, Highest unknown 
impurity and Total Impurities 
obtained from method precision 
and intermediate precision 
results should not be more than 
10.0                                                                                                                         
 
 
 
 
 
Robustness 
 
Variation in column 
oven temperature 
 
       
       Complies     
 
The over all % RSD of 
Known impurity, 
Highest unknown Impurity and 
Total Impurities obtained from 
method precision and 
robustness results should not be 
more than 10.0. 
 
Variation in flow rate 
         
      Complies     
 
Variation in mobile 
phase pH 
         
     Complies     
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. 
 
 
 
 
 
 
 
 
 
Degradation 
Study  
 
  
 
 
Acid stress 
 
 
 
 
         
   Complies     
 
 
        
 
 
   Complies     
 
  Complies     
 
  Complies     
 
 
      1.0 
 
 
Total Impurities should be 
±15% .The% RSD of peak 
responses between initial and 
bench top stability for diluted 
standard not more than 2.0. 
 
 
 
 
 
 
 
 
Total Impurities should be 
±15% .The% RSD of peak 
responses between initial and 
bench top stability for diluted 
standard not more than 2.0. 
 
 
The Peak Purity should be not 
less than 0.9 in open lab 
software / purity angle should 
less than purity threshold for 
Empower Software. 
 
 
Base stress 
 
Peroxide stress 
 
Thermal stress 
 
 
Peak purity 
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11.  SUMMARY AND CONCLUSION 
From the reported literature, there were few methods established for the determination of 
Cefixime was concluded that method reported for the Related substance of Cefixime oral 
suspension the above selected single component dosage form, which promote to pursue the 
present work. The scope and object of the present work is to develop and validate a new simple 
HPLC method for related substance of Cefixime Oral suspension dosage form. 
  In RP-HPLC method development, The Related substance of Cefixime oral suspension 
was carried out by using the Novapak  C 18 column (3.9 X 150 mm) with 4-micron particle size. 
Injection volume of 10µl is injected and eluted with the mobile phase phosphate Buffer, 
Acetonitrile with the gradient programme pH 6.5, which is pumped at the flow rate of 1.0 ml / 
min. Detection was carried out at 254 nm. Quantitation was done by calibration curve method 
with the above mentioned optimized chromatographic condition. This system produced 
symmetric peak shape, good resolution and reasonable retention times of   cefixime E isomer and 
cefixime   were found to be resolution is 3.0 and retension time is 30.8 and 33.02  minutes 
respectively. 
 The 0.4 µg/ml to 40 µg/ml of cefixime respectively. The slope intercept and correlation 
coefficient(s) were found to be, within the limit for which indicates excellent correlation factor 
Vs concentration of standard solutions.Precision of the developed methods was studied under 
system precision, method precision. The %RSD values for precision was found to be within the 
acceptable limit, which revealed that the developed method was precise. The developed method 
was found to be robust. The %RSD values for recovery percentage of Cefixime was found to be 
within the acceptable criteria. The result indicates satisfactory accuracy of method for estimation 
of the above mentioned drugs.Hence, the chromatographic method developed for Cefixime  are 
rapid, simple, specific, sensitive, precise, Accurate. The RP-HPLC was simple and does not 
suffer from common excipients in pharmaceutical preparation and highly useful in the analysis 
of drugs in pharmaceutical formulation.   
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